Search

Your search keyword '"Hayden, Patrick John"' showing total 14 results
Start Over Author "Hayden, Patrick John"
14 results on '"Hayden, Patrick John"'

1. Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers

Author

Garderet, Laurent, primary, Gras, Luuk, additional, Koster, Linda, additional, D'Souza, Anita, additional, Estrada-Merly, Noel, additional, Hari, Parameswaran, additional, Saber, Wael, additional, Cowan, Andrew J., additional, Iida, Minako, additional, Okamoto, Shinichiro, additional, Takamatsu, Hiroyuki, additional, Mizuno, Shohei, additional, Kawamura, Koji, additional, Kodera, Yoshihisa, additional, Hamad, Nada, additional, Ko, Bor-Sheng, additional, Liam, Christopher, additional, HO, KIM Wah, additional, Sim Goh, A., additional, Keat Tan, S., additional, Elhaddad, Alaa M., additional, Bazarbachi, Ali, additional, Chaudhry, Qamar un Nisa, additional, Alfar, Rozan, additional, Bekadja, Mohamed-Amine, additional, Benakli, Malek, additional, Frutos Ortiz, Cristobal Augusto, additional, Riva, Eloisa, additional, Galeano, Sebastian, additional, Bass, Francisca, additional, Mian, Hira S., additional, McCurdy, Arleigh, additional, Wang, Feng Rong, additional, Neumann, Daniel, additional, Koh, Mickey, additional, Snowden, John A., additional, Schönland, Stefan, additional, McLornan, Donal P., additional, Hayden, Patrick John, additional, Sureda, Anna, additional, Greinix, Hildegard T., additional, Aljurf, Mahmoud, additional, Atsuta, Yoshiko, additional, and Niederwieser, Dietger, additional

Published
2022
Full Text
View/download PDF

2. International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation

Author

Garderet, Laurent, primary, Gras, Luuk, additional, Koster, Linda, additional, D'Souza, Anita, additional, Estrada-Merly, Noel, additional, Hari, Parameswaran, additional, Saber, Wael, additional, Cowan, Andrew J, additional, Iida, Minako, additional, Okamoto, Shinichiro, additional, Takamatsu, Hiroyuki, additional, Mizuno, Shohei, additional, Kawamura, Koji, additional, Kodera, Yoshihisa, additional, Hamad, Nada, additional, Ko, Bor-Sheng, additional, Liam, Christopher, additional, Ho, Kim Wah, additional, Sim Goh, A, additional, Keat Tan, S, additional, Elhaddad, Alaa M., additional, Bazarbachi, Ali, additional, Chaudhry, Qamar un Nisa, additional, Alfar, Rozan, additional, Bekadja, Mohamed-Amine, additional, Benakli, Malek, additional, Frutos Ortiz, Cristobal Augusto, additional, Riva, Eloisa, additional, Galeano, Sebastian, additional, Bass, Francisca, additional, Mian, Hira S, additional, McCurdy, Arleigh, additional, Wang, Feng Rong, additional, Neumann, Daniel, additional, Koh, Mickey, additional, Snowden, John A, additional, Schönland, Stefan, additional, McLornan, Donal P., additional, Hayden, Patrick John, additional, Sureda, Anna, additional, Greinix, Hildegard T., additional, Aljurf, Mahmoud, additional, Atsuta, Yoshiko, additional, and Niederwieser, Dietger, additional

Published
2022
Full Text
View/download PDF

3. Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Author

Hayden, Patrick John, primary, Eikema, Dirk-Jan, additional, Koster, Linda, additional, Snowden, John A, additional, Caillot, Denis, additional, Van Gorkom, Gwendolyn, additional, Griskevicius, Laimonas, additional, Arcese, William, additional, Crawley, Charles, additional, Musso, Maurizio, additional, Bulabois, Claude-Eric, additional, Martin, Alexander M, additional, Netelenbos, Tanja, additional, McDonald, Andrew, additional, Maertens, Johan, additional, Parma, Matteo, additional, Illes, Arpad, additional, Isaksson, Cecilia, additional, Sossa, Claudia, additional, Drozd-Sokolowska, Joanna, additional, Raj, Kavita, additional, Beksac, Meral, additional, Schönland, Stefan, additional, McLornan, Donal P., additional, and Yakoub-Agha, Ibrahim, additional

Published
2022
Full Text
View/download PDF

4. Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Author

Poiré, Xavier, primary, Eikeman, Diderik-jan, additional, Koster, Linda, additional, Maertens, Johan A., additional, Cornelissen, Jan J., additional, Fegueux, Nathalie, additional, Byrne, Jennifer, additional, Salmenniemi, Urpu, additional, Choi, Goda, additional, Chevallier, Patrice, additional, Kinsella, Francesca A, additional, Schroeder, Thomas, additional, Beguin, Yves, additional, Blaise, Didier, additional, Bourhis, Jean-Henri, additional, Kuball, Jurgen H.E., additional, Veelken, Hendrik, additional, Passweg, Jakob R., additional, Bermudez Rodriguez, Arancha, additional, Srour, Micha, additional, Hayden, Patrick John, additional, Onida, Francesco, additional, Scheid, Christof, additional, Robin, Marie, additional, and Yakoub-Agha, Ibrahim, additional

Published
2021
Full Text
View/download PDF

5. Comparative Study of Unrelated and Haploidentical Donor Hematopoietic Cell Transplant for Chronic Myeloid Leukemia with Post Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis: A Study from the Chronic Malignancies Working Party of EBMT

Author

Ortí, Guillermo, primary, Gras, Luuk, additional, Zinger, Nienke, additional, Kulagin, Aleksandr D., additional, Byrne, Jennifer, additional, Apperley, Jane F, additional, Halaburda, Kazimierz, additional, Blau, Igor Wolfgang, additional, Clark, Andrew, additional, Kröger, Nicolaus, additional, Griskevicius, Laimonas, additional, Carlson, Kristina, additional, Collin, Matthew P., additional, Bloor, Adrian, additional, Angelucci, Emanuele, additional, Blaise, Didier, additional, Aljurf, Mahmoud, additional, Lopez Corral, Lucia, additional, Anagnostopoulos, Achilles, additional, Beguin, Yves, additional, Wrobel, Tomasz, additional, Rigacci, Luigi, additional, Hayden, Patrick John, additional, Chalandon, Yves, additional, and Yakoub-Agha, Ibrahim, additional

Published
2021
Full Text
View/download PDF

6. Transplant Outcomes in Patients with Ph+ Chronic Myeloid Leukemia: Haploidentical Donors Compared to Matched Sibling Donors and Matched/Mismatched Unrelated Donors: A Retrospective Analysis from the EBMT Chronic Malignancies Working Party (EBMT-CMWP)

Author

Onida, Francesco, primary, Junran, Ge, additional, Koster, Linda, additional, Hamladji, Rose-Marie, additional, Byrne, Jennifer, additional, Potter, Victoria, additional, Aljurf, Mahmoud, additional, Robin, Marie, additional, Halaburda, Kazimierz, additional, Passweg, Jakob R., additional, Salmenniemi, Urpu, additional, Sengeloev, Henrik, additional, Apperley, Jane F, additional, Clark, Andrew, additional, Reményi, Péter, additional, Morozova, Elena V., additional, Craddock, Charles, additional, Lenhoff, Stig, additional, Ganser, Arnold, additional, Wu, Ka Lung, additional, Perez Martinez, Antonio, additional, Hayden, Patrick John, additional, Gras, Luuk, additional, Chalandon, Yves, additional, and Yakoub-Agha, Ibrahim, additional

Published
2021
Full Text
View/download PDF

7. A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Author

Beksac, Meral, primary, Iacobelli, Simona, additional, Koster, Linda, additional, Blaise, Didier, additional, Cornelissen, Jan J., additional, Reményi, Péter, additional, Leleu, Xavier, additional, Gedde-Dahl, Tobias, additional, Poire, Xavier, additional, Griskevicius, Laimonas, additional, Forcade, Edouard, additional, Lenhoff, Stig, additional, Rabin, Neil K, additional, Kobbe, Guido, additional, Netelenbos, Tanja, additional, Arcese, William, additional, Mear, Jean-Baptiste, additional, Engelhardt, Monika, additional, Pabst, Thomas, additional, Schaap, Nicolaas, additional, Sossa, Claudia Lucia, additional, Elmaagacli, Ahmet, additional, Hayden, Patrick John, additional, Schoenland, Stefan, additional, and Yakoub-Agha, Ibrahim, additional

Published
2021
Full Text
View/download PDF

8. Autologous and Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome: A Large Series from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Author

Tournilhac, Olivier, primary, Guièze, Romain, additional, Eikema, Dirk-Jan, additional, Zinger, Nienke, additional, Sengeloev, Henrik, additional, Passweg, Jakob R., additional, Nielsen, Bendt, additional, Poire, Xavier, additional, Byrne, Jenny, additional, Gramatzki, Martin, additional, Finke, Jürgen, additional, Cornelissen, Jan J, additional, Blaise, D, additional, Nikolousis, Emmanouil, additional, Chevallier, Patrice, additional, Van Gorkom, Gwendolyn, additional, Ringhoffer, Mark, additional, Mordini, Nicola, additional, de Wreede, Liesbeth C., additional, Hayden, Patrick John, additional, van Gelder, Michel, additional, and Yakoub-Agha, Ibrahim, additional

Published
2019
Full Text
View/download PDF

9. Outcomes Following Second Allogenic Haematopoietic Cell Transplantation in Patients with Myelofibrosis: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of EBMT

Author

Nabergoj, Mitja, primary, Wang, Junfeng, primary, Robin, Marie, primary, Kröger, Nicolaus, primary, Angelucci, Emanuele, primary, Poire, Xavier, primary, Passweg, Jakob R., primary, Dreger, Peter, primary, Platzbecker, Uwe, primary, Robinson, Stephen, primary, Rambaldi, Alessandro, primary, Sengeloev, Henrik, primary, Bornhäuser, Martin, primary, Stelljes, Matthias, primary, Ciceri, Fabio, primary, Mayer, Jiri, primary, Ladetto, Marco, primary, de Wreede, Liesbeth C., primary, Koster, Linda, primary, Hayden, Patrick John, primary, Czerw, Tomasz, primary, Hernandez Boluda, Juan Carlos, primary, McLornan, Donal P., primary, Chalandon, Yves, primary, and Yakoub-Agha, Ibrahim, primary

Published
2019
Full Text
View/download PDF

10. A New Method for Estimating Treatment-Related Mortality for Older Patients

Author

de Wreede, Liesbeth C., primary, Schetelig, Johannes, additional, Putter, Hein, additional, van Biezen, Anja, additional, Koster, Linda, additional, Iacobelli, Simona, additional, Perme, Maja Pohar, additional, van Gelder, Michel, additional, Scheid, Christof, additional, Schoenland, Stefan, additional, Hayden, Patrick John, additional, Yakoub-Agha, Ibrahim, additional, Robin, Marie, additional, and Kroeger, Nicolaus, additional

Published
2019
Full Text
View/download PDF

11. Long Term Outcomes and Renal Response Following Autologous Stem Cell Transplantation for Light Chain Deposition Disease:a Retrospective Study on Behalf of the Cmwp of the EBMT

Author

Garderet, Laurent, Gras, Luuk, Koster, Linda, Rovira, Montserrat, Vincent, Laure, Kobbe, Guido, Pillai, Srinivas, Deeren, Dries, Kaufmann, Martin, Kuball, Jurgen, Ozdogu, Hakan, Pascual, Maria Jesús, Passweg, Jakob R., Rye, Adam, Salmenniemi, Urpu, Snowden, John, Stauffer Larsen, Thomas, Leleu, Xavier, Gastaud, Lauris, Drozd-Sokolowska, Joanna, Raj, Kavita, Beksac, Meral, Schonland, Stefan, Hayden, Patrick John, and McLornan, Donal P

Abstract

Background: There is a paucity of data concerning long-term outcomes following autologous stem cell transplantation (ASCT) for light chain deposition disease (LCDD). The goal of this retrospective study was to analyze the outcomes following ASCT in LCDD patients in terms of toxicity and efficacy with both hematological and renal responses.

Published
2023
Full Text
View/download PDF

12. Allogeneic Hematopoietic Cell Transplantation for Vexas Syndrome: Results of a Multicenter Study from the Chronic Malignancies and Autoimmune Disease Working Parties of the EBMT

Author

Gurnari, Carmelo, Koster, Linda, Baaij, Laurien, Heiblig, Mael, Yakoub-Agha, Ibrahim, Passweg, Jakob R., Clay, Jennifer, Kuball, Jurgen, Rambaldi, Alessandro, Hayden, Patrick John, Badoglio, Manuela, Onida, Francesco, Scheid, Christof, Franceschini, Franco, Mekinian, Arsene, Savic, Sinisa, Voso, Maria Teresa, Drozd-Sokolowska, Joanna, Snowden, John, Raj, Kavita, Alexander, Tobias, Robin, Marie, Greco, Raffaella, and McLornan, Donal P

Abstract

VEXAS is a new entity encompassing a variety of clinical manifestations spanning from autoimmune/auto-inflammatory to hematologic conditions including MDS, plasma cell dyscrasias, and recurrent thrombosis. Somatic mutations of the X-linked UBA1gene in hematopoietic stem and progenitor cells constitute the molecular underpinnings of VEXAS, typically occurring in men during the 6 thdecade of life. Over the last 2 years since its first description, VEXAS has elicited wide medical interest resulting in the identification of pleomorphic clinical phenotypes, which make this syndrome a “big masquerader” and a clinical diagnostic challenge. Treatment strategies aim at suppression of the UBA1-mutant clone (e.g., with azacitidine or allo-HCT) or blockade of the downstream pleiotropic effects of hypercytokinemia. However, no treatment guidelines exist to date, and patients may manifest life-threatening inflammatory symptoms frequently refractory to many therapies. As few literature reports have described the successful use of transplant, we here report the outcomes of patients with VEXAS in a multicenter EBMT registry-based study.

Published
2023
Full Text
View/download PDF

13. Salvage Transplant Versus CAR-T Cell Therapy for Relapsed Multiple Myeloma

Author

Gagelmann, Nico, Garderet, Laurent, Iacobelli, Simona, Koster, Linda, Carotti, Alessandra, Schönland, Stefan, Galieni, Piero, Daskalakis, Michael, Roeloffzen, Wilfried, Hunter, Hannah, Duchosal, Michel A., Lenhoff, Stig, Arat, Mutlu, Wulf, Gerald G., Bolam, Simon, Pastore, Domenico, Gedde-Dahl, Tobias, Richardson, Deborah Susan, Mielke, Stephan, Raj, Kavita, Drozd-Sokolowska, Joanna, Hayden, Patrick John, and McLornan, Donal P

Abstract

Background:Ide-cel and cilta-cel received regulatory approval for the treatment of patients with relapsed or refractory multiple myeloma (MM) after ≥4 prior lines of therapy, and almost all eligible patients in the US and Europe have previously received at least one autologous hematopoietic cell transplant (autoHCT). Even for those who received upfront autoHCT, salvage transplant (either second autoHCT or allogeneic HCT) for patients with relapsed MM was shown to be effective and feasible. Therefore, comparing CAR-T cell therapy with salvage transplant could facilitate future selection of patients with relapsed MM, as eligibility for transplant (especially allogeneic HCT) differs significantly from that of CAR-T.

Published
2023
Full Text
View/download PDF

14. Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).

Author

Garderet L, Gras L, Koster L, Baaij L, Hamad N, Dsouza A, Estrada-Merly N, Hari P, Saber W, Cowan AJ, Iida M, Okamoto S, Takamatsu H, Mizuno S, Kawamura K, Kodera Y, Ko BS, Liam C, Ho KW, Goh AS, Tan SK, Elhaddad AM, Bazarbachi A, Chaudhry QUN, Alfar R, Bekadja MA, Benakli M, Ortiz CAF, Riva E, Galeano S, Bass F, Mian HS, McCurdy A, Wang FR, Meng L, Neumann D, Koh M, Snowden JA, Schönland S, McLornan DP, Hayden PJ, Sureda A, Greinix HT, Aljurf M, Atsuta Y, and Niederwieser D

Abstract

Autologous hematopoietic cell transplantation (AHCT) is a commonly used treatment in multiple myeloma (MM). However, real-world global demographic and outcome data are scarce. We collected data on baseline characteristics and outcomes from 61 725 patients with newly diagnosed MM who underwent upfront AHCT between 2013 and 2017 from nine national/international registries. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), relapse incidence (RI) and non-relapse mortality (NRM). Median OS amounted to 90.2 months (95% CI 88.2-93.6) and median PFS 36.5 months (95% CI 36.1-37.0). At 24 months, cumulative RI was 33% (95% CI 32.5%-33.4%) and NRM was 2.5% (95% CI 2.3%-2.6%). In the multivariate analysis, superior outcomes were associated with younger age, IgG subtype, complete hematological response at auto-HCT, Karnofsky score of 100%, international staging scoring (ISS) stage 1, HCT-comorbidity index (CI) 0, standard cytogenetic risk, auto-HCT in recent years, and use of lenalidomide maintenance. There were differences in the baseline characteristics and outcomes between registries. While the NRM was 1%-3% at 12 months worldwide, the OS at 36 months was 69%-84%, RI at 12 months was 12%-24% and PFS at 36 months was 43%-63%. The variability in these outcomes is attributable to differences in patient and disease characteristics as well as the use of maintenance and macroeconomic factors. In conclusion, worldwide data indicate that AHCT in MM is a safe and effective therapy with an NRM of 1%-3% with considerable regional differences in OS, PFS, RI, and patient characteristics. Maintenance treatment post-AHCT had a beneficial effect on OS., (© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results